Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance. in Cancer investigation / Cancer Invest. 2025 Jan;43(1):59-69. doi: 10.1080/07357907.2024.2432013. Epub 2024 Nov 27.

2025
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tipo pubblicazione

Multicenter Study

Autori/Collaboratori (21)Vedi tutti...

Di Maio M
Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Brunetti O
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Spadi R
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

et alii...

Abstract

Despite a biologically established causative role of viral hepatitis (VH), i.e. HBV and HCV infections, on intrahepatic cholangiocarcinoma (ICC), only few large Western cohorts exploring the association between VH and ICC development are available. The prognostic significance of VH in ICC is debated, and no data are available regarding a predictive role for standard first-line CT (CT1), consisting of gemcitabine +/- platinoids. VH-positivity definition is often clinically incomplete and inconsistent among studies. Five different VH conditions, based on laboratory and anamnestic data, were investigated in a multicentric retrospective cohort of advanced ICC cases. Depending on the specific VH condition considered, 139-194 of 472 ICC cases could be categorized according to the presence of the mentioned VH conditions. VH prevalence ranged from 9.3 to 25.3%. No VH condition showed an impact on survival, although a non-significant worse outcome was observed for some HBV-related conditions. HCV-related conditions were associated to lower pre-CT1 biomarkers of inflammation, markedly higher disease control, and numerically longer time-to-progression with CT1. No benefit on time-to-progression was demonstrated for the addition of platinoids to gemcitabine in VH-positive patients (HR 0.77, CI(95%) 0.41-1.45), at least in HBV-related cases. These findings are clinically relevant and deserve further investigation.

Accesso banca dati bibliografica

PMID : 39601419

DOI : 10.1080/07357907.2024.2432013

Keywords

prognosis; biliary tract cancer; predictive value; HBV/HCV; Intrahepatic cholangiocarcinoma; Hepatitis B/epidemiology/complications; Hepatitis C/complications/epidemiology/drug therapy; Gemcitabine; Aged; Deoxycytidine/analogs & derivatives/therapeutic use; Prognosis; Prevalence; Middle Aged; Bile Duct Neoplasms/epidemiology/virology; Female; Male; Retrospective Studies; Cholangiocarcinoma/epidemiology/virology; Humans; viral hepatitis;